Study Summary
The present study is an exploratory study. Patients who meeting the enrollment conditions for relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells. The research with the open-label, single arm running control methods in order to initially observe the safety, tolerability, and cellular pharmacokinetics of CD20-CART cell drugs.
Want to learn more about this trial?
Request More InfoInterventions
CD20 CAR-T cellsDRUG
A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou | Jiangsu | China |